Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCT-guided ranibizumab retreatment in branch retinal vein occlusion macular edema
2012-005439-10Phase 2Completed
- Sponsor
- Leipzig University
- Start
- Jul 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab in branch retinal vein occlusion (BRVO) and macular edema, sponsored by Leipzig University. Primary endpoint: Change in best corrected visual acuity. Started Jul 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
branch retinal vein occlusion (BRVO)macular edema
Beyond the preview
Go deeper on 2012-005439-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005439-10.